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The mushroom Ganoderma lucidum (G. lucidum) has been consumed in China as
a medicine for promoting health and longevity for thousands of years. Due to its
paramount and multiple pharmaceutical effects, G. lucidum has received considerable
attention from researchers and its chemical constituents as well as their respective
functions were gradually unveiled by using modern research methods. Herein, we
reported the isolation of a protein (Ganoderma lucidum ribonuclease, GLR) with anti-
colorectal cancer activities from G. lucidum. This protein is a 17.4-kDa RNA degrading
enzyme (ribonuclease) and was purified by using liquid chromatography procedures.
GLR manifested potent anti-proliferative and anti-colony formation activities on HT29
and HCT116 colorectal cancer cells by inducing cell cycle arrest in G1 phase through
the regulation of cyclin D1 and P53 expression. GLR was demonstrated to induce
cell apoptosis in HCT116 cells by activating unfolded protein response and caspase-
9 regulated pathways. Besides, the ability to undergo autophagy which is a stress
adaption mechanism to cope with metabolic crisis was significantly suppressed by
GLR treatment in HCT116 cells. The activation of apoptosis in GLR-treated HT29 cells
was, however, independent of caspase-9 and the suppression of autophagy was also
relatively minor. Thus the apoptosis of HT29 cells triggered by GLR was much milder
than that in HCT116 cells. Our findings show that the RNase from G. lucidum may be
one of the bioactive components that contribute to the anti-colorectal cancer activity of
G. lucidum.
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INTRODUCTION
Ganoderma lucidum, which is also called “Lingzhi” in Chinese, “Reishi” in Japanese, and
“Youngzhi” in Korea, has been applied as traditional Chinese medicine to improve human vitality
and longevity since 2000 years ago (Weng and Yen, 2010; Cheng and Sliva, 2015). Though
its multiple functions have been recorded in the oldest Chinese medicinal book in 100 BC
Abbreviations: Apaf-1, apoptotic protease activating factor 1; CHOP, C/EBP homologous protein; ER, endoplasmic
reticulum; FPLC, Fast protein liquid chromatography; GLR, Ganoderma lucidum ribonuclease; GLPS, Ganoderma lucidum
polysaccharides; IRE1α, inositol requiring enzyme 1 α; PARP, poly (ADP-ribose) polymerase; PERK, pancreatic ER kinase
(PKR)-like ER kinase; PI, propidium iodide; RNase, ribonuclease; UPR, unfolded protein response.
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(Huie and Di, 2004), its pharmacological mechanisms have
only been partially unveiled in recent decades. Laboratory and
preclinical research has confirmed its anti-cancer, anti-bacterial,
and anti-inflammatory activities as well as its modulating effects
on immunity and cardiovascular diseases (Cheng and Sliva,
2015).
Triterpenoids and polysaccharides are the main constituents
contributing to its anti-cancer functions (Weng and Yen,
2010; Ruan et al., 2015). Currently, there are more than
130 oxygenated triterpenoids and over 200 polysaccharides
identified in G. lucidum (Huie and Di, 2004). Triterpenoids
have a bitter flavor and share similarities with steroid hormones
in structure. They exert anti-oxidative, anti-allergy and anti-
hypertensive bioactivities (Huie and Di, 2004). Polysaccharides
are macromolecules with diverse structures. Some of them
are water-soluble while others are water-insoluble (Huie and
Di, 2004). Many G. lucidum polysaccharides (GLPS) exert
immune-modulating functions through activating the expression
of cytokines associated with inflammatory response (like
interleukin-1, interleukin-6, and tumor necrosis factor-α) or anti-
tumor activity (like interferon-γ and tumor necrosis factor-α;
Chen et al., 2004). Though there are reports indicating a direct
cytotoxicity of GLPS on cancer cells (Liang et al., 2015), the anti-
cancer functions of GLPS are, however, still generally believed
to be closely associated with their immuno stimulating effects
(Paterson, 2006).
In addition to triterpenoids and polysaccharides, the bioactive
components of G. lucidum also include fatty acids, nucleosides,
amino acids, proteins, peptides, alkaloids, steroids, and enzymes
(Weng and Yen, 2010). The anti-cancer activity of ribonuclease
(RNase), an RNA degrading enzyme, is the focus of the present
paper. This type of protein is capable of catalyzing cleavage
of phosphodiester bonds in RNA (Ardelt et al., 2009) and
has been detected in different organisms, including animals,
plants, bacteria, and fungi (Fang and Ng, 2011). RNases
could be classified into two types, endoribonucleases and
exoribonucleases, and each type could be further classified into
different subtypes. RNases are not only important in clearing
unwanted cellular RNA but also important in controlling gene
expression, maturation, and turnover (Fang and Ng, 2011).
After entrance to the cytoplasm, foreign RNase could degrade
RNA and inhibit protein biosynthesis at both transcription and
translation stages (Ardelt et al., 2009). Though mammalian cells
usually contain a variety of ribonuclease inhibitors (RIs) to
protect RNA from unwanted degradation, these human RIs,
however, fail to inactivate the enzymatic activity of RNases
from bacteria and fungi (Allgood et al., 1990; Makarov and
Ilinskaya, 2003). The anti-tumor activity of RNases is directly
associated with catalytic cleavage activity on ribosomes since
catalytically inactive RNases are devoid of cytotoxicity. Among
the widely studied RNases, onconase is the smallest member
of the RNase A superfamily and demonstrates significant anti-
tumor functions by inducing cell apoptosis independent of P53
protein (Lee, 2008). It has now been successfully applied to
translational research clinically in the US and Europe (Lee, 2008),
indicating a tremendous potential of RNases to be applied in
cancer therapy.
MATERIALS AND METHODS
Materials and Agents
Ganoderma lucidum was collected on the campus of The Chinese
University of Hong Kong and authenticated by Prof. Shiuying
Hu, Honorary Professor of Chinese Medicine, The Chinese
University of Hong Kong. DEAE-Sepharose, Mono Q 5/50 GL,
Superdex 75 10/300 GL columns and Akta Purifier were bought
from GE Healthcare, UK. Primary antibodies against caspase-9,
CHOP, IRE1 α, and PARP and secondary antibody for anti-
rabbit lgG as well as anti-mouse lgG were purchased from
Cell Signaling (Danvers, MA, USA). Primary antibodies against
Apaf-1, ATF6, P62, and GAPDH were purchased from Abcam
(Cambridge, UK). Primary antibodies against cyclin D1, LC3 and
P53 were, respectively, purchased from Millipore (Billerica, MA,
USA), Novus (Littleton, CO, USA) and Calbiochem (La Jolla,
CA, USA). Click-iT EdU Imaging Kits were purchased from
Invitrogen. Image-iTTM LIVE Green Poly Caspases Detection
Kit was obtained from Life Technologies (Carlsbad, CA, USA).
WesternBrightTM ECL was purchased from Advansta (Menlo
Park, CA, USA).
Protein Purification
Fresh G. lucidum fruiting bodies (309 g) were first ground into
a slurry in double-distilled water containing 0.2 M NaCl and
stored at 4◦C overnight before centrifugation at 14000 rpm for
30 min at 4◦C. The supernatant was subjected to dialysis against
double-distilled water to remove salt before lyophilization. The
lyophilized powder was dissolved in 20 mM NH4HCO3 (pH 9.6)
buffer and subsequently loaded on a DEAE-Sepharose column
(5 cm × 17 cm; 340 ml bed volume) pre-equilibrated with
the same buffer. Unadsorbed fraction was eluted with 20 mM
NH4HCO3 (pH 9.6) buffer while the adsorbed fractions were
eluted with the same buffer containing 0.2 M, 0.5 M, and 1 M
NaCl successively. The bound fraction (eluted by 0.2 M NaCl)
from DEAE-Sepharose was then loaded on a Mono Q column
(5 mm× 50 mm; 1ml bed volume) pre-equilibrated with 20 mM
NH4HCO3 buffer (pH 9.6) on a FPLC system. The unbound and
bound proteins were, respectively, eluted with 20 mM NH4HCO3
buffer (pH 9.6) and the same buffer containing three successive
linear gradients of NaCl (0−0.2 M in 5 ml, 0.2−0.3 M in
15 ml, 0.3−1 M in 5 ml). The fraction containing the target
protein was collected and prepared for chromatography on a
Superdex 75 HR10/300 column (10 mm × 300 mm; 24 ml
bed volume) pre-equilibrated with 0.1 M NaCl in 20 mM Tris-
HCl buffer on the FPLC system. The isolated protein from
each step was dialyzed against water, lyophilized, dissolved in
the corresponding buffer before chromatography on the next
column.
Sodium Dodecyl Sulfate-Polyacrylamide
Gel Electrophoresis (SDS-PAGE) and
Mass Spectrometric Analysis
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis was
carried out by using a 12.5% resolving gel and a 5% stacking gel.
At the end of electrophoresis, the gel was stained with Coomassie
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Brilliant Blue and subsequently distained with 10% acetic acid
until the background was clear. The molecular weight of the
protein was estimated with reference to the molecular weight
marker and subsequently confirmed by mass spectrometric
analysis (UltrafleXtreme, Bruker). The purified protein was also
trypsinized to produce small peptides by using in-gel digestion
methods (Shevchenko et al., 2006) and analyzed by using a
HPLC system (Ultimate 3000, Dionex) and a mass spectrometer
(UltrafleXtreme, Bruker). The peptides were compared with
those of reported fungal proteins in NCBI and SWISS-PROT data
base.
Assay of Ribonuclease Activity
The ribonuclease activity of the purified protein was tested by
using the methods previously reported (Wang and Ng, 2006).
Briefly, the tested sample was incubated with 200 µg yeast tRNA
(Sigma) in 150 µl 100 mM MES buffer (pH 6.0) for 15 min before
the reaction was terminated by the addition of 350 µl ice-cold
perchloric acid (3.5%). The mixture was placed on ice for 15 min
and was subsequently centrifuged to obtain the supernatant. The
OD260 of the supernatant was measured and compared with the
negative control.
Assessment of pH and Thermal Stability
Purified protein was dissolved in buffer with different pH values
(over the pH range of 1−12) for 30 min at room temperature and
neutralized to pH 7 before ribonuclease activity was determined.
The activity of protein treated with buffer at pH 7 was taken
as the standard. To assess the thermal stability, protein was
incubated at different temperatures (20◦C to 100◦C) for 30 min
and subsequently fully cooled down to room temperature before
the assay for ribonuclease activity. The activity of the protein at
30◦C was taken as the standard.
Cell Proliferation Assay
Colorectal carcinoma HCT116 cells and colorectal
adenocarcinoma HT29 cells were cultured in RPMI-1640
medium with 10% fetal bovine serum (FBS) and 1%
penicillin/streptomycin (PS) at 37◦C. Cells (5 × 103 cells in
100 µl per well) were seeded and cultured for 24 h in a 96-well
microtiter plate before treatment with different concentrations
of the purified RNase for another 24 or 48 h. Cell viability
was then evaluated by the 3-(4, 5-dimethylthiazol-2yl)-2,
5-diphenyltetrazolium bromide (MTT) assay as described
previously (Dan et al., 2015).
Cells (3× 104) were seeded on the coverslips in 24-well culture
plates overnight before they were cultured in medium containing
1 µM GLR and 10 µM EdU for 24 h. Cells were then fixed in 3.7%
formaldehyde in PBS for 10 min at room temperature, followed
by permeabilization in 0.5% Triton X-100 for 20 min. The EdU
was then detected by following the instructions of the Click-iT
EdU imaging Kits (Invitrogen) by using Alexa Fluor R© 555 on a
confocal microscope (Olympus FV1000-ZCD).
Cell Colony Formation
Cells were seeded on a 6-well plate at the density of 2 × 103
cells per well and treated with different concentrations of RNase
for 48 h after cells had fully attached on the plate. At the
end of the treatment, cells were rinsed with PBS, supplied with
fresh medium and cultured for another 6 days, with medium
refreshed every three days. Cell colonies were observed by using
the ChemDoc XRS system after they had been fixed in 4%
formaldehyde and stained with crystal violet (0.4 g/L). Colony
size and numbers were compared between the wells treated with
and without the purified RNase by using Image-Pro Plus 6.0.
Detection of Poly-Caspases
The detection of polycaspase activation was performed by
following the instruction of the manufacturer of Image-iT LIVE
Green Poly Caspases Detection Kit. Briefly, cells were first treated
with 1 µM purified RNase for 24 h and subsequently cultured
in medium containing the reagent working solution for 60 min
in a cell culture incubator. Cells were carefully rinsed with PBS,
followed by incubation with 1 µM Hoechst 33342 for another
5 min in darkness. After removal of Hoechst 33342, cells were
supplied with fresh PBS and observed by using a Nikon Live Cell
Imaging System Ti-E.
Characterization Using Flow Cytometry
Cell apoptosis was monitored by the Annexin-V and PI double
staining method. Briefly, after treatment with RNase for 24 or
48 h, cells were collected and stained in binding buffer (0.01 M
HEPES, pH 7.4, 140 mM NaCl and 25 mM CaCl2) containing
0.5 mg/ml Annexin V (BDPharmingen, San Jose, CA, USA) and
5 µg/ml PI (Sigma−Aldrich, St. Louis, MO, USA) in the dark for
15 min before application on a flow cytometer.
For cell cycle analysis, the treated cells were successively fixed
in 70% ethanol on ice for 2 h, rinsed with enough PBS and stained
with 50 µg/ml PI for 15 min in darkness. The samples were
filtered through a nylon membrane before analysis on the flow
cytometer.
Western Blotting
Whole cell extracts prepared by using ice-cold RIPA lysis buffer
(150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1%
SDS, and 1 mM phenylmethylsulfonyl fluoride in 50 mM Tris-
HCl buffer, pH 8.0) were applied for Western blotting with
procedures as described previously (Dan et al., 2015). Briefly,
supernatants of the cell extracts were loaded on SDS-PAGE for
electrophoresis and subsequently transferred to a polyvinylidene
fluoride membrane, followed by blocking in 5% milk. The
membrane was then incubated with the first antibody overnight
at 4◦C and the second antibody at room temperature for 2 h.
Bands were finally visualized by using WesternBrightTM ECL
(Advansta).
Assessment Using Transmission
Electron Microscope (TEM)
Cells were collected after treatment with 1 µM GLR for 24 h
and rinsed with PBS before fixation in 2.5% glutaraldehyde for
1 h. TEM Samples were prepared by using the method that
has been previously reported (Dan et al., 2016). The prepared
sample sections were successively stained with uranyl acetate and
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lead citrate before final examination with a transmission electron
microscope (Hitachi H-7700).
Cell Transfection
The pEGFP-LC3 expression plasmid was a generous gift from
Professor Xiaoqiang Yao (School of Biomedical Sciences, The
Chinese University of Hong Kong, Hong Kong). Briefly, pEGFP-
LC3 (human) was purchased from Addgene and amplified
by using DH5a. The plasmid was then transfected into cells
by using Lipofectamine 2000 (Invitrogen) by following the
manufacturer’s protocols. Six-four hours after transfection, cells
were trypsinized, seeded on coverslips and cultured in complete
medium overnight before treatment with 2 µM GLR for
another 48h. Cells were fixed in 3.7% formaldehyde and viewed
with a confocal fluorescence microscope (Olympus FV1000-
ZCD).
Statistical Analysis
Results were taken from three independent experiments (n = 3)
and data were expressed as means ± standard deviation (SD).
Scatter diagram and histograms were drawn using GraphPad
Prim 5 (Graphpad Software, La Jolla, CA, USA). Students’ t-test
and one-way ANOVA followed by Bonferronni post hoc test were,
respectively, applied to the comparison between two groups and
multiple group comparison. A p-value < 0.05 was considered as
statistically significant: ∗P< 0.05; ∗∗P< 0.01; ∗∗∗P< 0.001 versus
respective control groups.
RESULTS
Protein Purification and Characterization
The crude extract of G. lucidum was first separated into
four fractions after chromatography on DEAE-Sepharose
(Figure 1A). The second fraction (D2) eluted with 0.2 M NaCl
contained the target protein after testing for ribonuclease activity.
This fraction was then further fractionated by using a Mono
Q column into four major fractions (M1, M2, M3, and M4)
(Figure 1B). The third fraction M3 which exhibited ribounclease
activity was collected for the next step of purification on a size
exclusion Superdex 75 HR10/300 chromatography column.
Based on the differences in molecular weight, proteins in fraction
M3 were further resolved into three major fractions (S1, S2,
and S3), as illustrated in Figure 1C. The second fraction S2
was demonstrated to have ribonuclease activity. Fraction S2
was then collected after dialysis against double-distilled water
and lyophilization. The gel electrophoresis pattern (shown in
Figure 1D) revealed that S2 contained only the target protein.
According to the results of mass spectrometry which showed a
peak at 17408.302 (Figure 1E), GLR had a molecular weight of
17.4 kDa. A yield of 42 mg purified RNase was obtained from
309 g fresh G. lucidum. A diagram illustrating the procedures
is presented in Figure 1F. The purified RNase from G. lucidum
was referred to as GLR in this text. The small peptides acquired
from trypsinized GLR were dissimilar to any of those reported
fungal proteins found in the database of Swiss-Prot and NCBI
after mass spectrometry analysis.
GLR exhibited the highest ribonuclease activity in a weakly
acidic environment (pH 5) and remained stable over a pH range
of 2−9 (with more than 90% of activity remaining), as shown by
Figure 1G. With reference to Figure 1H, the ribonuclease activity
of GLR was intact up to 50◦C and it was attenuated by only 5 and
25% after exposure to 60 and 100◦C, respectively.
GLR Exhibited Cell Toxicity in Colorectal
Cancer Cells
The viability of both HT29 and HCT116 cells was suppressed by
treatment with GLR in a time- and dose-dependent manner. As
illustrated in Figure 2A, GLR demonstrated a stronger inhibitory
effect on the proliferation of HCT116 cells than that on HT29
cells at 24 h. At the time point of 48 h (Figure 2B), the divergence
was still observable when cells were treated with GLR at a
concentration lower than 9 µM. The IC50 (at 48 h) values for
HT29 cells and HCT116 cells were, respectively, about 2.8 and
0.1 µM, indicating a higher sensitivity of HCT116 cells than
HT29 cells to GLR treatment.
In keeping with results of cell proliferation assay, GLR
treatment also strongly suppressed the colony forming ability of
colorectal cancer cells. As shown in Figures 2C,D, the number of
cell colonies was reduced by around 30% in both HT29 cells and
HCT116 cell treated with 1 µM GLR. Besides, the colony sizes
of both types of cells receiving the treatment of 1 µM GLR were
reduced by more than 50% compared with that of the control.
GLR Induced Cell Cycle Arrest at G1
Phase
To elucidate the possible mechanism of the anti-proliferative
activity of GLR on colorectal cancer cells, its modulatory effect on
the cell cycle was monitored. The percentages of cells at different
phases of the cell cycle were compared between cells cultured
without GLR and cells cultured in the presence of different
concentrations of GLR. As shown in Figure 3A, after colorectal
cancer cells had been treated with 0, 1, or 2 µM GLR for 24 h, the
percentage of cells in G1 phase increased from 52.23% (0 µM) to
59.48% (1 µM) or 68.54% (2 µM) in HT29 cells and from 35.19%
(0 µM) to 49.57% (1 µM), or 54.57% (2 µM) in HCT116 cells,
indicating a cell cycle arresting function of GLR. EdU labeling
confirmed that GLR significantly reduced DNA synthesis of both
types of colorectal cancer cells, as shown in Figure 3B.
In line with this result, the expression of cyclin D1 and
P53 which play vital roles in cell proliferation was, respectively,
downregulated and up-regulated in a time- and dose-dependent
manner (Figures 3C,D).
GLR Increased UPR
The UPR is important for the homeostasis of protein-folding
within the ER. IRE1α, activating transcription factor 6 (ATF6)
and PKR-like ER kinase (PERK) are the three important
sensor proteins for endoplasmic reticulum stress (ERS). They
play vital roles in the activation of UPR by transmitting the
information across the membrane to the cytosol (Gardner et al.,
2013). These three stress sensors were upregulated in both
HT29 and HCT116 cells treated with GLR, as displayed in
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FIGURE 1 | Isolation of GLR. (A) Aqueous extract of Ganoderma lucidum was first loaded on a DEAE-Sepharose column. The adsorbed fractions were obtained
by eluting the column with different concentrations of NaCl (represented by the dashed lines). Peak D2 containing the highest ribonuclease activity was collected.
(B) Adsorbed peak D2 was subsequently loaded on a Mono Q column and the adsorbed fractions were eluted with three successive linear gradients of NaCl
(0−0.2 M in 5 ml, 0.2−0.3 M in 15 ml, and 0.3−1 M in 5 ml). (C) The only peak with ribonuclease activity, M3, collected in the previous step was subjected to
Superdex 75 10/300 GL column to yield purified RNase (peak S2). (D) SDS-PAGE showing purity and molecular weight of GLR (peak S2). From the left to the right,
the lanes represented the bound fraction D2 from DEAE-Sepharose, the bound fraction M3 from Mono Q, fraction S2 from Superdex 75 and molecular weight
marker proteins, respectively. (E) Mass spectrometry results indicated that the acquired S2 fraction had a molecular weight of 17408.302 kDa. (F) Schematic
representation of the chromatographic steps used for the purification. Square frame and ellipse, respectively, represented the applied column and collected fractions.
(G) pH stability of GLR was measured after incubation in buffers of different pH values for 30 min at room temperature. (H) Thermal stability of GLR was tested after
incubation at different temperatures. The remaining ribonuclease activity of treated GLR in (G) and (H) was tested by using yeast tRNA as substrate (n = 3).
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FIGURE 2 | Cytotoxicity of GLR on colorectal cancer cells. HT29 cells and HCT116 cells were exposed to different concentrations of GLR for 24 h (A) and 48 h
(B). MTT assay was used to assess cell viability. In the colony formation assay, cells were first cultured with medium containing 0, 0.5, or 1 µM GLR for 48 h and
subsequently allowed to grow in normal culture medium for 6 days. (C) The colony number (and colony size were monitored for comparison. (D) The representative
images of colonies. ∗P < 0.05; ∗∗P < 0.01, ∗∗∗P < 0.001 versus respective control groups.
Figure 4. However, the expression of IRE1α and PERK in
GLR treated HCT116 cells was first up-regulated at the initial
stage of treatment and then downregulated at 48h. Though
UPR is a cytoprotective mechanism for cells to adapt to altered
environments, UPR becomes cytotoxic and may induce cell
apoptosis under conditions of severe and prolonged ER stress
(Gardner et al., 2013). In the present scenario, the expression
of CHOP which is one of the components of the ER stress-
mediated apoptosis pathway (Oyadomari and Mori, 2004) was
found to be upregulated (Figure 4), indicating a possibility of
apoptosis-inducing effect of GLR on colorectal cancer cells.
GLR Activated Apoptosis
In order to confirm whether GLR treatment could induce cell
apoptosis in colorectal cancer cells, Annexin V/PI staining was
applied for evaluation of phosphatidylserine exposure. As shown
in Figure 5A, for HT29 cells, no obvious difference in the
percentage of apoptotic cells was observed between GLR-treated
cells and untreated cells at the time point of 24h. However, in
HCT116 cells, respectively 4.4, 13, and 25.4% of cells receiving
0, 1, and 2 µM GLR were undergoing early apoptosis at 24 h.
At the time point of 48h in GLR-treated HT29 cells, around
19 and 24% of apoptotic cells treated with 1 and 2 µM GLR
demonstrated apoptosis. For HCT116 cells exposed to 1 and
2 µM GLR, over 44 and 70% of the cells were found to undergo
obvious apoptosis.
The activation of caspases under the stimulation of GLR
was evaluated by using Image-iT LIVE Green Poly Caspases
Detection Kit. After the cells had been treated with 1 µM GLR for
24 h, polycaspases signal was detected in GLR-treated HCT116
cells, but not in GLR-treated HT29 cells (Figure 5B). This result
was consistent with those of the Annexin V/PI staining assay in
that at the time point of 24 h, apoptosis was triggered only in
GLR-treated HCT116 cells.
To reveal a more detailed activation process of cell apoptosis,
we had monitored the expression of Apaf-1, apoptosis regulator
BAX and an initiator caspase (caspase-9). Though BAX was
upregulated by GLR treatment in both HT29 cells and HCT116
cells, the expression of Apaf-1 and activated caspase-9 was
upregulated only in GLR-treated HCT116 cells (Figures 5C,D).
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FIGURE 3 | Ganoderma lucidum ribonuclease induced cell cycle arrest at G1 phase. (A) HT29 and HCT116 cells were treated with different concentrations
of GLR for 24 h. Cells were fixed in ice-cold ethanol and stained with PI for flow cytometric analysis. (B) Cells were seeded on the coverslips in a 24-well plate and
cultured in the presence of 1 µM GLR and 10 µM EdU for 24 h. Cells were observed by using a confocal microscope after the labeling of Alexa Fluor R© 555. The
percentage of EdU positive cells was displayed in the right panel (n = 3). ∗∗P < 0.01, ∗∗∗P < 0.001 versus respective control groups. (C) Western blotting analysis of
cyclin D1 expression in HT29 (C) and HCT116 cells (D) was conducted after cells had been treated with indicated concentrations of GLR for 24 or 48 h. GAPDH
was used as an internal control.
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FIGURE 4 | Ganoderma lucidum ribonuclease promoted UPR in colorectal cancer cells. After treatment with GLR at the indicated concentrations for 24 or
48 h, the protein levels of IRE1α, ATF6, PERK, caspase-12, and CHOP in HT29 cells (A) and HCT116 cells (B) were determined by western blotting. GAPDH was
used as an internal control.
Despite the inactivation of caspase-9, cleavage of PARP was still
discernible in GLR-treated HT29 cells at 48 h, which indicated
that apoptosis was also triggered in HT29 cells after treatment
with GLR for a longer duration (48 h). Compared with HT29
cells, the cleavage of PARP in GLR-treated HCT116 cells was
triggered at an earlier stage (24 h) and to a larger extent.
GLR Suppressed Cell Autophagy
Intriguingly, GLR was found to suppress cell autophagy in both
HT29 cells and HCT116 cells. As evidenced in Figure 6A,
accumulation of P62, upregulation of LC3-I and downregulation
of LC3-II were detected in cells receiving GLR. These two
phenomena were particularly conspicuous in HCT116 cells.
pEGFP-LC3 labeling results indicated greater abundance of
LC3 protein in GLR-treated HCT116 cells and a portion of GLR-
treated HT29 cells than in the respective control cells when
the images were taken under the same conditions (Figure 6B).
GLR-treated cells also showed more green fluorescent spots.
TEM analysis of autophagic vacuoles (AVs) (Figure 6C)
in both types of colorectal cancer cells indicated that GLR
treatment did not induce an increase of autophagic vacuoles in
the cytoplasm of the cells.
DISCUSSION
In the present research, we purified a ribonuclease from
G. lucidum through the application of chromatographic
procedures. The molecular mass of GLR isolated in the present
study was 17.4 kDa, which lies within the range 9.5 to 45 kDa
reported for mushroom RNases (Kobayashi et al., 2003; Ngai
et al., 2003). Though a least two RNases have been reported
from G. lucidum, including a 42 kDa RNase (Wang et al.,
2004) and an RNase with gene named RNGI30, GLR was
dissimilar to any of the reported fungal proteins as judged by
molecular weight or MS analysis. However, GLR resembled
RNases from Lyophyllum shimeiji ( Zhang et al., 2010), Ramaria
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FIGURE 5 | Ganoderma lucidum ribonuclease induced cell apoptosis in colorectal cancer cells. (A) Cells exposed to the indicated concentrations of GLR
for 24 or 48 h were harvested and subsequently stained with Annexin V/PI solution. Cells were then sorted by using flow cytometry. (B) Cells were treated with GLR
at the indicated concentrations for 24 h, and nuclear morphological changes and caspase activation were, respectively, examined by staining with Hoechst 33342
and image-iT LIVE Green Poly Caspases staining reagent. Bars, 200 µm. Expression of Apaf-1, Bax, caspase-9, and PARP in HT29 cells (C) and HCT116 cells (D)
was analyzed by western blotting after cells had been treated with different concentrations of GLR for 24 or 48 h. GAPDH was used as an internal control.
formosa (Zhang et al., 2015), Russulus virescens (Wang and
Ng, 2003), and Thelephora ganbajun (Wang and Ng, 2004)
in adsorption on DEAE-cellulose and Q-ion exchangers, and
differed from Hypsizigus marmoreus (Guan et al., 2007) and
Russula delica RNases (Zhao et al., 2010) which were unadsorbed
on DEAE-cellulose.
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FIGURE 6 | Ganoderma lucidum ribonuclease suppressed the activation of cell autophagy in colorectal cancer cells. (A) HT29 cells and HCT116 cells
were treated with the indicated concentrations of GLR for different durations before the protein expression levels of P62, LC3-I, and LC3-II were determined by
western blotting. GAPDH was used as an internal control. (B) Subcellular expression and distributions of pEGFP-LC3. Colorectal cancer cells were transfected with
the pEGFP-LC3 vectors in OPTI-MEM I Reduced Serum Medium for 6 h. After treatment with 2 µM GLR for 48 h, the fluorescence signals of cells were acquired by
confocal microscopy. (C) Ultrastructures of HT29 cells and HCT116 cells treated with or without GLR. Cells were cultured with medium containing 0 or 1 µM GLR
for 24 h before preparation for TEM sections. N, nucleus; M, mitochondrion; AVs, autophagic vacuoles.
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Ribonucleases have been found in a variety of organisms,
encompassing plants (Green, 1994; Podzimek et al., 2011),
fungi (Fang and Ng, 2011), bacteria (Aphahasenko et al., 1979),
and animals (Newton et al., 1997). Some of the ribonucleases
were reported to be immunosuppressive, embrytoxic, or
aspermatogenic (Leland and Raines, 2001) and some of them
demonstrated potent anti-tumor activity (Piccoli et al., 1999;
Fang and Ng, 2011; Zhang et al., 2010; Fiorini et al., 2015). The
present article constitutes the first report on induction of cell
cycle arrest and apoptosis by G. lucidum RNase.
When HCT116 cells and HT29 cells were, respectively, treated
with 3 and 8 µM GLR for 48h, proliferation of both types of cells
was suppressed by more than 80%. At the early stage of treatment
(24 h), the proliferation of HCT116 cells tended to be inhibited
to a significantly higher degree than that of HT29 cells receiving
the same dosage of GLR and this difference was attenuated but
still discernible at 48 h. This result indicated a time and effect
divergence of GLR’s inhibitory function on these two types of
colorectal cancer cells. Further assessment indicated that GLR
could induce cell cycle arrest in G1 phase by downregulating
the expression of cyclin D1 and upregulating the expression of
P53. The proto-oncogene protein cyclin D1 is overexpressed in
a variety of cancers, including colon cancer (Arber et al., 1997),
breast cancer (Lin et al., 2000), and lung cancer (Gautschi et al.,
2007) etc. to advance cell cycle progression from G1 phase to S
phase. The report of Arber et al. (1997) provided direct evidence
for the critical role of cyclin D1 in maintaining the malignant
phenotype of colon cancer cells and pointed out its potential
application as a cancer marker and a target for cancer therapy.
As evidenced in Figures 3C,D, cyclin D1 was indeed prominently
detected in the untreated colorectal cancer cells and its expression
was adjustable by GLR treatment, indicating the great potential of
GLR to target the overexpressed cyclin D1 in colorectal cancer.
Though GLR triggered cell apoptosis in both HT29 cells and
HCT116 cells, the apoptotic pathways in these two cells lines
were, however, a little bit different. Cleavage of PARP in GLR-
treated HT29 cells was conducted independently of caspase-9
and Apaf-1 (as shown in Figure 5C). PARP is a zinc-finger
DNA-binding protein and it is implicated in the maintenance of
genomic stability and DNA damage repair. Once it is cleaved by
caspases which may be caspase-3 or caspase-7, it becomes inactive
and loses the ability to respond to DNA damage and promotes cell
apoptosis (Yang et al., 2004). The activation of caspase-3 which
is upstream of PARP cleavage could be activated in a caspase-
9 dependent and independent way (Porter and Janicke, 1999),
which explains the possibility of PARP cleavage in the absence
of caspase-9 activation. In the present case, the cleavage of PARP
in GLR-treated HT29 cells could most probably be regulated
through ER stress-mediated pathways which usually involve
transcriptional activation of the gene for CHOP, activation of
the cJUN NH2-terminal kinase (JNK) pathway or activation of
caspase-12(Oyadomari and Mori, 2004). Among the aforesaid
pathways, we have detected the upregulation of caspase-12 and
CHOP in GLR-treated HT29 cells. Accordingly, the expression of
three stress sensors IRE1α, ATF6 and PERK was also upregulated.
Different from HT29 cells, HCT116 cells receiving the same
treatment of GLR were found to undergo apoptosis by both
activating caspase-9 and ER stress, which led to an earlier and
more obvious cleavage of PARP than in GLR-treated HT29 cells.
Autophagy is a natural and destructive process that degrades
unwanted or dysfunctional cellular proteins, organelles and bulk
cytoplasm (Cuervo et al., 2005). It is a cellular response to a
variety of stresses like nutritional starvation (Scott et al., 2004),
hypoxia (Bellot et al., 2009), and drug treatment (Lei and Chang,
2007) etc. It could function both as a stress adaptive mechanism
to avoid cell death and also promote programmed cell death type
II (Lei and Chang, 2009). The specific role of autophagy in cell
fate is context-dependent. Due to the continuing uncontrolled
proliferation of cancer cells, the supply of sufficient energy
and nutrition is critical, especially when the cancer cells are
under the stimulation of metabolic stress, like starvation. In this
case, autophagy is usually employed by cells to recycle cellular
constituents from dysfunctional cells to survive metabolic stress
and inhibition of autophagy could accelerate cell apoptosis (Boya
et al., 2005). In the present study, suppression of autophagy was
detected in both HT29 and HCT116 colorectal cancer cells after
treatment with GLR, as observed in Figure 6. Accumulation of
P62 was discerned as early as 24 h post-GLR treatment at the
dosage of 1 µM in HCT116 cells while significant accumulation
of P62 in HT29 cells was detected only at a later time point (48 h)
and a higher concentration of GLR. Besides, downregulation of
LC3-II in GLR-treated HCT116 cells was much more significant
than that observed in GLR-treated HT29 cells. However, when
LC3 was overexpressed in HT29 cells and HCT116 cells by
using transfection vectors, the overall fluorescence signal of LC3
and fluorescent spots were more abundantly detected in GLR-
treated cells than untreated cells. This phenomenon was again
especially obvious in GLR-treated HCT116 while it was only
observed in a portion of GLR-treated HT29 cells. The abundance
of LC3 in GLR-treated cells may be explained by the blockage
of autophagic degradation which led to accumulation of LC3
and P62. However, further studies are still needed to confirm
this speculation. Generally, GLR induced more severe autophagy
suppression in HCT116 cells than in HT29 cells and this may help
explain why GLR triggered more potent apoptosis in HCT116
cells than it did in HT29 cells, which would then help explain why
GLR exhibited a higher toxicity on HCT116 cells than HT29 cells.
Then why did GLR trigger more severe autophagy dysfunction
in HCT116 cells than HT29 cells? This may be attributed to the
difference in protein transport efficiency or enzyme expression in
the two cells lines.
To sum up, the RNase which was isolated from G. lucidum
in the present investigation could undermine the proliferation of
colorectal cancer cells by downregulating cyclin D1 and inducing
cell cycle arrest. This Rnase was capable of triggering UPR
and autophagy dysfunction, which then induced apoptosis in
colorectal cancer cells.
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